Tredje AP fonden Has $24.85 Million Position in Align Technology, Inc. $ALGN

Tredje AP fonden increased its position in shares of Align Technology, Inc. (NASDAQ:ALGN) by 13.9% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 131,232 shares of the medical equipment provider’s stock after purchasing an additional 16,034 shares during the quarter. Tredje AP fonden’s holdings in Align Technology were worth $24,846,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Redmond Asset Management LLC lifted its holdings in Align Technology by 2.0% during the 1st quarter. Redmond Asset Management LLC now owns 2,769 shares of the medical equipment provider’s stock worth $440,000 after purchasing an additional 54 shares during the last quarter. Horizon Investments LLC lifted its holdings in Align Technology by 6.2% during the 1st quarter. Horizon Investments LLC now owns 1,018 shares of the medical equipment provider’s stock worth $162,000 after purchasing an additional 59 shares during the last quarter. Atria Investments Inc lifted its holdings in Align Technology by 4.9% during the 2nd quarter. Atria Investments Inc now owns 1,575 shares of the medical equipment provider’s stock worth $298,000 after purchasing an additional 74 shares during the last quarter. IFP Advisors Inc lifted its holdings in Align Technology by 5.7% during the 2nd quarter. IFP Advisors Inc now owns 1,427 shares of the medical equipment provider’s stock worth $270,000 after purchasing an additional 77 shares during the last quarter. Finally, Covestor Ltd lifted its holdings in Align Technology by 18.8% during the 1st quarter. Covestor Ltd now owns 493 shares of the medical equipment provider’s stock worth $78,000 after purchasing an additional 78 shares during the last quarter. 88.43% of the stock is owned by institutional investors and hedge funds.

Align Technology Price Performance

Align Technology stock opened at $137.88 on Friday. Align Technology, Inc. has a one year low of $122.00 and a one year high of $246.19. The stock’s fifty day moving average price is $133.23 and its two-hundred day moving average price is $161.79. The firm has a market cap of $9.99 billion, a PE ratio of 26.72, a price-to-earnings-growth ratio of 1.49 and a beta of 1.70.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings results on Wednesday, October 29th. The medical equipment provider reported $2.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.23. Align Technology had a return on equity of 14.06% and a net margin of 9.50%.The company had revenue of $995.69 million for the quarter, compared to analyst estimates of $980.75 million. During the same quarter last year, the company posted $2.35 EPS. The company’s revenue for the quarter was up 1.8% compared to the same quarter last year. Align Technology has set its Q4 2025 guidance at EPS. Sell-side analysts expect that Align Technology, Inc. will post 7.98 earnings per share for the current fiscal year.

Align Technology declared that its Board of Directors has initiated a stock buyback plan on Tuesday, August 5th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

ALGN has been the subject of several research reports. Zacks Research raised Align Technology from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 30th. Wells Fargo & Company lowered their price objective on Align Technology from $199.00 to $181.00 and set an “overweight” rating on the stock in a research note on Thursday. Jefferies Financial Group raised their price objective on Align Technology from $140.00 to $155.00 in a research note on Thursday. Weiss Ratings lowered Align Technology from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, October 8th. Finally, Morgan Stanley raised their price objective on Align Technology from $142.00 to $154.00 and gave the stock an “equal weight” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $175.45.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.